Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PROCEPT BioRobotics ( (PRCT) ) has provided an update.
On February 26, 2026, PROCEPT BioRobotics held an Investor and Analyst Day at Nasdaq’s New York headquarters to outline its next chapter of growth in the BPH treatment market. Management highlighted that Aquablation penetration in the U.S. remains low relative to the roughly 40 million men living with BPH, underscoring a substantial runway for procedure and installed-base expansion.
The company reported more than 125,000 Aquablation procedures performed worldwide and a global installed base exceeding 900 systems, supported by Category I reimbursement in the U.S. as of January 1, 2026. Leadership emphasized improved organizational discipline, noting higher-than-expected handpiece pricing and a rising ratio of handpiece sales to procedures, which together are enhancing revenue quality and the path to profitability.
PROCEPT detailed a realignment of its commercial organization to put single-point accountability at the regional level, with area vice presidents and regional directors overseeing both capital sales and clinical procedure support. This structure is designed to accelerate procedure growth and reinforce Aquablation’s push toward becoming a standard of care for BPH surgery.
The company also introduced dedicated launch teams separating capital and procedure functions to more effectively open new accounts and grow procedure volume at existing sites. In pilot accounts during the fourth quarter of 2025, this launch model reduced the time from purchase order to the first ten cases by about 50%, suggesting a meaningful operational boost for hospitals and a faster ramp in system utilization.
The most recent analyst rating on (PRCT) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
The overall stock score is primarily influenced by financial performance and technical analysis. Despite strong revenue growth, the company faces significant challenges in profitability and cash flow, which are critical concerns. Technical indicators point to bearish momentum, further impacting the score. Valuation metrics are weak due to negative earnings and lack of dividends, adding to the negative outlook.
To see Spark’s full report on PRCT stock, click here.
More about PROCEPT BioRobotics
PROCEPT BioRobotics is a medical technology company focused on robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a common condition among aging men. Its core offerings include the AQUABEAM and HYDROS Robotic Systems that deliver Aquablation therapy, targeting a large, underpenetrated BPH market in which many patients remain undertreated or fear existing surgical options.
Average Trading Volume: 1,273,326
Technical Sentiment Signal: Sell
Current Market Cap: $1.52B
See more insights into PRCT stock on TipRanks’ Stock Analysis page.